Shareholders to Vote on New 2026 Equity Incentive Plan Authorizing up to 7.5M Shares

summarizeSummary

Xenon Pharmaceuticals is proposing a new 2026 Equity Incentive Plan for shareholder approval, which would make approximately 7.5 million shares available for future grants, representing a potential dilution of about 7.76% of current outstanding shares, to support talent retention and growth.

check_boxKey Events

• New Equity Incentive Plan Proposed

  Shareholders will vote on the 2026 Equity Incentive Plan, which would authorize 4.4 million new shares and allow for the recycling of up to 14.7 million shares from the prior plan, totaling approximately 7.5 million shares available for future grants under all equity plans.

• Potential Dilution

  If all shares available for new grants under the proposed plan are issued, it represents a potential dilution of approximately 7.76% of the current outstanding shares.

• Shareholder-Friendly Features Included

  The new plan includes provisions such as no evergreen clause, prohibition of repricing without shareholder approval, and no automatic vesting of awards upon a change of control.

• Annual Meeting Scheduled

  The annual shareholder meeting will be held virtually on June 2, 2026, to vote on director elections, executive compensation, auditor appointment, and the new equity plan.

auto_awesomeAnalysis

Xenon Pharmaceuticals is seeking shareholder approval for its 2026 Equity Incentive Plan at the upcoming annual meeting. This plan would authorize 4.4 million new common shares for issuance and allow for the recycling of additional shares from the previous plan, resulting in approximately 7.5 million shares available for future grants under all equity plans. This represents a potential dilution of about 7.76% of the current outstanding shares. The company emphasizes that this plan is crucial for attracting and retaining talent as it transitions to a commercial-stage company, noting that failure to approve could necessitate increased cash compensation. The plan incorporates shareholder-friendly features, including no evergreen provision, a prohibition on repricing awards without shareholder approval, and no automatic vesting upon a change of control.